Usage Examples
- The RFD came back with CDRH as lead center, so this files as a PMA with a CDER consult on the drug constituent part.
- Part 4 lets us run one quality system, but the drug constituent part still carries its Part 211 obligations.
- Postmarket reporting splits: malfunction reports on the delivery system, fifteen-day reports on the drug.
What is Combination Product?
A combination product is a medical product composed of two or more regulated constituent parts - drug, device, or biological - that FDA regulates through one lead center, assigned by the constituent part providing the product's primary mode of action.
Combination products exist because FDA's review machinery was built around three separate product classes, each with its own center, application type, and quality regulation. A prefilled syringe, a drug-eluting stent, and an autoinjector each belong to more than one class at once. 21 CFR Part 3 resolves the conflict by naming one lead center per product instead of forcing two parallel reviews.
A combination product covers four configurations under 21 CFR 3.2(e): constituent parts combined or mixed into a single entity; two products packaged together as a unit; a separately packaged product labeled for use only with a specified approved product whose labeling must change; and the investigational equivalent. Products merely used together, with no cross-labeling dependency, fall outside the definition.
A combination product is worked in practice through three decisions. Which center leads, settled by primary mode of action and, when contested, by a Request for Designation. Which manufacturing framework governs, settled under 21 CFR Part 4. And how postmarket safety reports are split, which follows the constituent parts rather than the lead center that approved the product.
Not to be confused with
- 510(k)
- a 510(k) is a marketing pathway; combination product is a jurisdictional classification. The classification decides which center owns the review, after which the product still goes through a 510(k), PMA, NDA, or BLA.
- 21 CFR Part 820
- Part 820 sets device quality system requirements for the device constituent part only. Part 4 is the layer above it, governing how Part 820 and drug CGMP coexist inside one manufacturing operation.
- Request for Designation
- an RFD is the procedure for settling which center leads. A product meeting 21 CFR 3.2(e) is a combination product whether or not an RFD is ever filed; the RFD resolves jurisdiction, it does not create the status.
- Co-packaged same-type kits
- 21 CFR 3.2(e)(2) requires the packaged unit to contain products of different types (drug and device, device and biological, or biological and drug). A tray of devices packed together for convenience is not a combination product.
The obligations attach to the constituent parts, not only to the lead center that reviews the application.
What you must do
- 1Determine the primary mode of action and route premarket review to the matching center: drugs to the drug component, devices to the device component, biological products to the biological products component21 CFR 3.4(a)
- 2Classify the product against all four configurations before assuming it is out of scope, including the cross-labeled case where a separately packaged product is intended for use only with a specified product21 CFR 3.2(e)
- 3File a Request for Designation when the lead center is unclear or disputed, and plan for the product jurisdiction officer to issue the letter of designation within 60 days of the filing date21 CFR 3.8(b)
- 4Apply drug CGMP under 21 CFR Parts 210 and 211 to the drug constituent part and device quality system requirements under 21 CFR Part 820 to the device constituent part, in a single operating system21 CFR 4.3
- 5File postmarket safety reports drawn from both regimes, including five-day reports, malfunction reports, and correction or removal reports on the device side alongside the drug-side reports21 CFR 4.102
Common mistakes
Assuming the lead center's rulebook is the only rulebook
designation under 21 CFR 3.4 sets premarket jurisdiction, not manufacturing or safety-reporting scope. A device-led combination product still carries drug CGMP obligations for its drug constituent part under 21 CFR 4.3. Sites that build a device-only quality system get the gap written up at inspection, after the product is already approved and shipping.
Filing the Request for Designation late
the product jurisdiction officer has 60 days from the filing date to issue the letter of designation [21 CFR 3.8(b)]. Teams that file after the pre-submission is drafted absorb those 60 days into the critical path, and a designation that lands on the other center invalidates the application type, the testing plan, and the submission structure already built around it.
Running one postmarket reporting stream
21 CFR 4.102 requires report types drawn from both regimes at once: five-day, malfunction, and correction or removal reports for the device constituent part alongside drug-side reporting. A pharmacovigilance group set up only for drug reporting will miss device malfunction events entirely, and missed malfunction reporting is a standard enforcement finding.
When This Matters
- The RFD came back with CDRH as lead center, so this files as a PMA with a CDER consult on the drug constituent part.
- Part 4 lets us run one quality system, but the drug constituent part still carries its Part 211 obligations.
- Postmarket reporting splits: malfunction reports on the delivery system, fifteen-day reports on the drug.
Frequently Asked Questions
The primary mode of action determines it: the mode expected to make the greatest contribution to the overall intended therapeutic effects. A drug primary mode routes to CDER, a biological one to CBER, a device one to CDRH. Where no mode dominates with reasonable certainty, FDA assigns the product to the component handling similar safety and effectiveness questions.
Related Use Cases
- Medical Devices Use Cases
Prepare 510(k), PMA, and De Novo submissions with AI-guided pathway selection
- Consulting Use Cases
Manage 15+ client programs from one dashboard with per-client workspaces and tracking
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
